Articles

A double-barrel approach

Peptide drug targets two cancer proteins for increased specificity and uptake
Written byKelsey Kaustinen
| 2 min read

From left to right, Dr. Law Ga-lai, Prof. Gary Wong Ka-Leung, and Dr. Lung Hong Lok—three of the key researchers on a team that a is working on a dual-targeting drug for cancers linked to the Epstein-Barr virus. CREDIT: Hong Kong Baptist University

HONG KONG—You may expect to find a two-for-one deal at a local shoe store, but probably not at a cancer clinic. Recent work published in Advanced Science may change your mind—researchers from Hong Kong Baptist University (HKBU) developed a dual-targeting drug for cancers linked to the Epstein-Barr virus (EBV).

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.